Aug 16, 2017
Top Pharma News of the Week
Top Pharma News of the Week
FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
Aug. 07, 2017
FibroGen, Inc., a science-based biopharmaceutical company, has announced positive topline results from the company’s Phase 2 randomized, double-blind, placebo-controlled study and two combination safety sub-studies of pamrevlumab in patients with idiopathic pulmonary…
View On WordPress